Company: IMCR
Filing Date: 2025-03-17
Form Type: 424B7
Source: 0001140361-25-008917
Chunk: 7

Company: Immunocore Holdings plc
Filing Date: 2025-03-17
Form: 424B7
Chunk 7
---
 of Proceeds
We will not receive any proceeds from the sale of the notes or the note conversion ADSs covered by this prospectus supplement.

#### Nasdaq Global Select Market Symbol
Our ADSs are listed for trading on the Nasdaq Global Select Market under the symbol “IMCR.”

The notes are listed on the Exchange under the symbol “IMMUNO30.” The Exchange is not a regulated market for the purposes of The Markets in Financial Instruments Directive (2004/39/EC). There is currently no established trading market for the notes in the United States and we do not expect a market to develop. We do not intend to list the notes on Nasdaq or any other national securities exchange or any other nationally recognized trading system in the United States. Without an active trading market, the liquidity of the notes will be limited.

#### Risk Factors
Investing in our securities involves a high degree of risk. See “Risk Factors” in this prospectus supplement and the sections captioned “Risk Factors” contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the SEC on February 26, 2025 and in our other filings that are incorporated by reference in this prospectus supplement.

<div align='center'>S-3</div>

#### TABLE OF CONTENTS

### THE NOTES

#### Maturity
February 1, 2030, unless earlier converted, redeemed or repurchased.

#### Interest
2.50% per year, payable semiannually in arrears on February 1 and August 1 of each year, beginning on August 1, 2024. We will pay additional interest, if any, at our election as the sole remedy relating to the failure to comply with our reporting obligations as described in the section titled “Description of Notes—Events of Default.”

#### Conversion Rights
Holders may convert all or any portion of their notes, in integral multiples of $1,000 principal amount, at their option at any time prior to the close of business on the business day immediately preceding the maturity date.

The conversion rate for the notes is initially 10.5601 ADSs, each representing as of the date of this prospectus supplement one ordinary share, per $1,000 principal amount of notes (equivalent to an initial conversion price of approximately $94.70 per ADS), subject to adjustment as described in this prospectus supplement.

Except in the circumstances described in the section titled “Description of Notes—Conversion Rights—Conversion Share